tbuckley/cabot-search huggingface dataset:
A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis
Authors: Angela Dispenzieri, Morie Abraham A. Gertz, Suzanne R. Hayman, Francis Buadi, Shaji Kumar, Craig B. Reeder, Joseph R. Mikhael, Steven Zeldenrust, S. Vincent Rajkumar, Kristen Detweiler-Short, Philip R. Greipp, Stephen J. Russell, David Dingli, Jacob Allred, Kristina Laumann, Rafael Fonseca, P. Leif Bergsagel, Vivek Roy, Keith Stewart, Martha Lacy
Journal: Blood (2010)
Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative Interventions for Myeloma and Its Associated Bone Disease.
Authors: Angela Pennisi, Xin Li, Maurizio Zangari, Jeffrey R. Sawyer, Fenghuang Zhan, Bart Barlogie, John Shaughnessy, Shmuel Yaccoby
Journal: Blood (2007)
Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study
Authors: Tulio de Oliveira, Ayesha B M Kharsany, Tiago Gräf, Cherie Cawood, David Khanyile, Anneke Grobler, Adrian Puren, Savathree Madurai, Cheryl Baxter, Quarraisha Abdool Karim, Salim S Abdool Karim
Journal: The Lancet HIV (2016)
Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Authors: Marcos de Lima, Simrit Parmar, Julianne J Chen, Sergio A Giralt, Gabriela Rondon, Uday R. Popat, Amin M. Alousi, Hans C. Lee, Glenda G Woodworth, Chitra M Hosing, Elizabeth J. Shpall, Partow Kebriaei, Guillermo garcia Manero, Richard E. Champlin, Rima M. Saliba
Journal: Blood (2012)
Cdk5 Directly Targets Nuclear p21CIP1 and Promotes Cancer Cell Growth
Authors: Pao-Hsuan Huang, Mei-Chih Chen, Yu-Ting Peng, Wei-Hsiang Kao, Chih-Hsiang Chang, Yun-Chi Wang, Chih-Ho Lai, Jer-Tsong Hsieh, Jo-Hsin Wang, Yueh-Tsung Lee, Eugene Lin, Chia-Herng Yue, Hsin-Yi Wang, Shuen-Chi You, Ho Lin
Journal: Cancer Research (2016)

Abstract The significance of Cdk5 in cell-cycle control and cancer biology has gained increased attention. Here we report the inverse correlation between the protein levels of Cdk5 and p21CIP1 from cell-based and clinical analysis. Mechanistically, we identify that Cdk5 overexpression triggers the proteasome-dependent degradation of p21CIP1 through a S130 phosphorylation in a Cdk2-independent manner. Besides, the evidence from cell-based and clinical analysis shows that Cdk5 primarily regulates nuclear p21CIP1 protein degradation. S130A-p21CIP1 mutant enables to block either its protein degradation or the increase of cancer cell growth caused by Cdk5. Notably, Cdk5-triggered p21CIP1 targeting primarily appears in S-phase, while Cdk5 overexpression increases the activation of Cdk2 and its interaction with DNA polymerase δ. The in vivo results show that Cdk2 might play an important role in the downstream signaling to Cdk5. In summary, these findings suggest that Cdk5 in a high expression status promotes cancer growth by directly and rapidly releasing p21CIP1-dependent cell-cycle inhibition and subsequent Cdk2 activation, which illustrates an oncogenic role of Cdk5 potentially applied for future diagnosis and therapy. Cancer Res; 76(23); 6888–900. ©2016 AACR.
VEGF 2578 c&gt;a, a Functional Angiogenic Polymorphism, Is Associated with Aggressiveness and Clinical Outcome of Follicular Lymphoma
Authors: Guilherme Rossi Assis de Mendonça, Angelo Borsarelli Carvalho Brito, Rodrigo de Andrade Natal, Marcia T Delamain, Carmino Antonio De Souza, Gisele W. B. Colleoni, José Vassallo, Carmen Silvia Passos Lima
Journal: Blood (2014)
A Novel Cytokine, FPT025, Regulates Myeloid Growth and Differentiation Via the M-CSF Receptor.
Authors: Haishan Lin, Min Mei Huang, Cindy Leo, May Ji, Ge Wu, Aileen Zhou, Robert Halenbeck, Minmin Qin, Thomas Linnemann, Dirk Behrens, Scott Giese, Elizabeth Bosch, Katrina Justin, Amber Pham, Ernestine Lee, Kevin Hestir, Hongbing Zhang, Justin Wong, Yan Wang, Keting Chu, Steve Doberstein, Lewis T. Williams, Diane Hollenbaugh
Journal: Blood (2006)
Crystal Structure of the Integrin αIIBβ3 Headpiece at 2.7–3.1 Å: Structure, Mechanisms of Activation and Ligand Binding, Inhibition by Eptifibatide, Tirofiban, and mAb 10E5, and Structure of the HPA-1 Alloantigen Epitope.
Authors: Timothy A. Springer, Junichi Takagi, Barry S. Coller, Jia-Huai Wang, Tsan Xiao
Journal: Blood (2004)
Elevated Tricuspid Regurgitation Jet Velocity on Echocardiogram In Patients with Sickle Cell Disease Is Associated with Worse Steady State Functional Class, Poor Lung Function and Low Haemoglobin but Not Other Markers of Haemolysis or Endothelin-1.
Authors: Harpreet Ranu, Emma Connell, Clare Hunt, Frances Boa, Jayne Lee, Luise Brown, Fenella Willis, Hubertus Buyck, Brendan Madden
Journal: Blood (2010)
Improving T Cell Therapy for Relapsed EBV-Negative Hodgkin's Lymphoma by Targeting Upregulated MAGE-A4
Authors: Conrad Russell Y. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Heslop, Catherine M. Bollard
Journal: Blood (2011)
Cyclosporine, but Not mTOR Inhibitors, Hampers the Reconstitution of Bone Marrow-Derived Tregs in Long-Term Complete Donor chimeras .
Authors: Haruko Sugiyama, Yoshinobu Maeda, Hisakazu Nishimori, Koichiro Kobayashi, Miyuki Nishie-Kataoka, Takanori Teshima, Mitsune Tanimoto
Journal: Blood (2008)
Selective Silencing of the NPM1 Mutant Protein and Apoptosis Induction upon ATRA In Vitro Treatment of AML Cells Carrying NPM1 Mutations.
Authors: M.P. Martelli, V. Pettirossi, N. Manes, A. Liso, F. Mezzasoma, F. Cecchetti, M.F. De Marco, B. Bigerna, A. Pucciarini, I. Nicoletti, M.F. Martelli, B. Falini
Journal: Blood (2007)
Symptomatic Multiple Myeloma in Young Adults ≤ 40 Years of Age.
Authors: Argiris Symeonidis, Anastasia Pouli, Panagiotis Repoussis, Konstantinos Zervas, Athanasios Anagnostopoulos, Chrysanthi Mitsouli, Dimitra Gika, Alice Maniatis, Meletios Athanasios Dimopoulos
Journal: Blood (2004)
A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective
Authors: Robyn Burton, Clive Henn, Don Lavoie, Rosanna O'Connor, Clare Perkins, Kate Sweeney, Felix Greaves, Brian Ferguson, Caryl Beynon, Annalisa Belloni, Virginia Musto, John Marsden, Nick Sheron
Journal: The Lancet (2016)
Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder
Authors: Ousseny Zerbo, Yinge Qian, Cathleen Yoshida, Bruce H. Fireman, Nicola P. Klein, Lisa A. Croen
Journal: JAMA Pediatrics (2016)

Maternal infections and fever during pregnancy are associated with increased risk for autism spectrum disorders (ASDs). To our knowledge, no study has investigated the association between influenza vaccination during pregnancy and ASD.To investigate the association between influenza infection and vaccination during pregnancy and ASD risk.This cohort study included 196 929 children born at Kaiser Permanente Northern California from January 1, 2000 to December 31, 2010, at a gestational age of at least 24 weeks.Data on maternal influenza infection and vaccination from conception date to delivery date, obtained from Kaiser Permanente Northern California inpatient and outpatient databases. Influenza infection was defined by the International Classification of Diseases, Ninth Revision, Clinical Modification codes or positive influenza laboratory test results.Clinical diagnoses of ASDs identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 299.0, 299.8, or 299.9 recorded in Kaiser Permanente Northern California electronic medical records on at least 2 occasions any time from birth through June 2015.Within this cohort of 196 929 children, influenza was diagnosed in 1400 (0.7%) mothers and 45 231 (23%) received an influenza vaccination during pregnancy. The mean (SD) ages of vaccinated and unvaccinated women were 31.6 (5.2) and 30.4 (5.6) years, respectively. A total number of 3101 (1.6%) children were diagnosed with ASD. After adjusting for covariates, we found that maternal influenza infection (adjusted hazard ratio, 1.04; 95% CI, 0.68-1.58) or influenza vaccination (adjusted hazard ratio, 1.10; 95% CI, 1.00-1.21) anytime during pregnancy was not associated with increased ASD risk. In trimester-specific analyses, first-trimester influenza vaccination was the only period associated with increased ASD risk (adjusted hazard ratio, 1.20; 95% CI, 1.04-1.39). However, this association could be due to chance (P = 0.1) if Bonferroni corrected for the multiplicity of hypotheses tested (n = 8). Maternal influenza vaccination in the second or third trimester was not associated with increased ASD risk.There was no association between maternal influenza infection anytime during pregnancy and increased ASD risk. There was a suggestion of increased ASD risk among children whose mothers received an influenza vaccination in their first trimester, but the association was not statistically significant after adjusting for multiple comparisons, indicating that the finding could be due to chance. These findings do not call for changes in vaccine policy or practice, but do suggest the need for additional studies on maternal influenza vaccination and autism.
SHANK3 Deficiency Impairs Heat Hyperalgesia and TRPV1 Signaling in Primary Sensory Neurons
Authors: Qingjian Han, Yong Ho Kim, Xiaoming Wang, Di Liu, Zhi-Jun Zhang, Alexandra L. Bey, Mark Lay, Wonseok Chang, Temugin Berta, Yan Zhang, Yong-Hui Jiang, Ru-Rong Ji
Journal: Neuron (2016)
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients
Authors: Ilaria Iacobucci, Annalisa Lonetti, Anna Candoni, Marco Sazzini, Serena Formica, Emanuela Ottaviani, Anna Ferrari, Cristina Papayannidis, Angela Michelutti, Eleonora Toffoletti, Annalisa Astolfi, Stefania Paolini, Mariachiara Abbenante, Sarah Parisi, Domenico Russo, Daniela Damiani, Filippo Gherlinzoni, Michele Gottardi, Michele Baccarani, Renato Fanin, Giovanni Martinelli
Journal: Blood (2010)
Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease
Authors: Jennifer A. Woyach, Matthew R Stefanovski, Virginia Goettl, Amy S. Ruppert, Kelly A Smucker, Lisa L. Smith, Jason A Dubovsky, William H. Towns, Jessica MacMurray, Melanie E. Davis, Yicheng Mao, Betty Y. Chang, Joseph J. Buggy, John C. Byrd, Amy J Johnson
Journal: Blood (2012)
Automated Screening for Genomic Imbalances in Multiple Myeloma Using Microarray-Based Comparative Genomic Hybridization (mCGH).
Authors: Christiane Wendl, Bernhard Radlwimmer, Swen Wessendorf, Carsten Schwaenen, Hartmut Döhner, Peter Lichter, Peter Liebisch
Journal: Blood (2005)
The Effect of Eltrombopag on Human Platelet Resistance to Apoptosis: The Role of the Bcl-Xl Pathway
Authors: W. Beau Mitchell, Michele N Edison, Mariana P Pinheiro, Nayla Boulad, Bethan Psaila, Marissa Karpoff, David Kaplan, Benjamin T Kile, Michael J White, Emma C Josefsson, James B. Bussel
Journal: Blood (2010)
Second Cord Blood Transplantation for Relapsed Myeloid Malignancies Following Allogeneic Transplantation – a Single Institute Analysis for 85 Recipients
Authors: Mitsuhiro Yuasa, Hisashi Yamamoto, Kosei Kageyama, Daisuke Kaji, Sachie Wada, Aya Nishida, Shinsuke Takagi, Masanori Tsuji, Go Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Koji Izutsu, Atsushi Wake, Akiko Yoneyama, Shigeyoshi Makino, Shuichi Taniguchi
Journal: Blood (2014)
Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study
Authors: Uwe Platzbecker, Ulrich Germing, Aristoteles Giagounidis, Katharina Götze, Philipp Kiewe, Karin Tina Mayer, Oliver Ottmann, Markus Radsak, Thomas Wolff, Detlef Haase, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie
Journal: Blood (2015)
Elevated Plasma Thrombospondin-1 (TSP1) Levels Are Correlated with Oxidative Stress and Worse Cognitive Function in Sickle Cell Disease
Authors: Enrico M Novelli, Lynda Little-Ihrig, Dana Rae Jorgensen, C Elizabeth Shaaban, Jeffrey S Isenberg, Meryl A Butters, Caterina Rosano
Journal: Blood (2015)
Integrated Epigenomic Profiling Reveals Aberrant DNA Hypomethylation in LGL and Demonstrates That a Combination of Genetic and Epigenetic Events Results in Leukemic Evolution in Model of Large Granular Lymphocytic Leukemia.
Authors: J. Opalinska, M. Daibata, D. Sohal, L. Zhou, R. Thompson, P. Pahanish, M. Affer, M. Figueroa, K. Ye, J. Greally, F. Bai, A. List, A. Melnick, P. Epling-Burnette, A. Verma
Journal: Blood (2007)
Increased Prevalence of Asthma Symptoms in Nigerian Children with Sickle Cell Disease Compared to Children without Sickle Cell Disease
Authors: Najibah Aliyu Galadanci, Wayne Liang, Muktar Aliyu, Binta Wudil Jibir, Ibraheem Karaye, Baba PD Inusa, Sten Vermund, Michael R. DeBaun
Journal: Blood (2012)
Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia.
Authors: Enzi Jiang, Eugene Park, Carlton Scharman, Yao-Te Hsieh, Asha Kadavallore, Cu Nguyen, Yi Zhao, Michael McMillan, John Groffen, Nora Heisterkamp, Markus Muschen, Michael Kahn, Yong-Mi Kim
Journal: Blood (2009)
Dexamethasone Dose and Schedule Significantly Influences Remission Rate and Toxicity of Induction Therapy in Adult Acute Lymphoblastic Leukemia (ALL): Results of the GMALL Pilot Trial 06/99.
Authors: Nicola Goekbuget, Karl-Heinz Baur, Joachim Beck, Helmut Diedrich, Monika Lamprecht, Lothar Leimer, Thomas Lipp, Jutta Neteler, Regina Reutzel, Jan Rutjes, Mathias Schmid, Peter Staib, Matthias Stelljes, Dieter Hoelzer
Journal: Blood (2005)
Hematopoietic Stem Cell Transplant Activity in Latin America: Predominant Increase in Autologous and Modest Increase in Allogeneic HCT with High Use of Unrelated Cord Blood Grafts
Authors: Juliana Martinez Rolon, Helen Baldomero, Gregorio Jaimovich, Maria Rivas, Luis Fernando Bouzas, Carmem Maria Sales Bonfim, Julia Palma, Amado Karduss-Urueta, Diana Ubidia, Willem Bujan-Boza, Oscar Gonzalez-Ramella, Guillermo J. Ruiz-Arguelles, David Gomez-Almaguer, German A. Espino, Ernesto Fanilla, Derlis Gonzalez, Antonio Carrasco, Sebastian Galeano, Walter Gabriel Borelli, Marcos Hernandez Gimenez, Marcelo C. Pasquini, Yoshihisa Kodera, Dietger Niederwieser, Adriana Seber
Journal: Blood (2015)
B Cell Reconstitution after Gene Therapy in Patients with Wiskott Aldrich Syndrome and Comparison with Mismatched Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Alessandra Magnani, Cécile Roudaut, Aurelie Gabrion, Laure Caccavelli, Fabien Touzot, Benedicte Neven, Despina Moshous, Nizar Mahlaoui, Emmanuel Clave, Antoine Toubert, Alain Fischer, Marina Cavazzana
Journal: Blood (2015)
A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Authors: Bing Xu, Yin Li, Kai Chen, Yong Zhou, Yiren Xiao, Manman Deng, Zhiwu Jiang, Wei Ye, Xinru Wei, Xiangmeng Wang, Jie Li, Jiabao Liang, Zhongxin Zheng, Yao Yao, Weiguang Wang, Peng Li
Journal: Blood (2015)
Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study)
Authors: Harpreet S. Bajaj, Karri Venn, Chenglin Ye, Avril Patrick, Shivani Kalra, Hasnain Khandwala, Nadeem Aslam, David Twum-Barima, Ronnie Aronson
Journal: Diabetes Care (2016)

There is a dearth of published literature comparing glucose variability (GV) between different insulin regimens in type 2 diabetes. This cohort study compares GV using continuous glucose monitoring (CGM) in patients with well-controlled type 2 diabetes using four common insulin regimens: basal insulin + oral drugs (BO), basal insulin + glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), premixed insulin (PM), and basal-bolus insulin (BB).Consecutive patients from three endocrinology clinics who met study criteria-type 2 diabetes, age 18 to 80 years, BMI ≤ 45 kg/m2, stable insulin regimen for a minimum of 6 months, and stable A1C value ≤7.5% (58 mmol/mol) before study enrollment-underwent 6-day masked CGM. Hypoglycemia was defined as a sensor glucose concentration <70 mg/dL on CGM.A total of 160 patients with comparable baseline characteristics formed four equal insulin regimen cohorts. The daily glucose SD (the primary outcome) was significantly lower in the BGLP cohort versus the BO, PM, and BB cohorts (P = 0.03, P = 0.01, and P < 0.01, respectively), and remained so after adjusting for age, BMI, type 2 diabetes duration, and A1C. Similarly, daily hypoglycemia outcomes on CGM were least for the BGLP cohort.The lowest GV and lowest hypoglycemia were observed in patients using the combination of basal insulin with a GLP-1 RA, supporting the complementary glycemic action of these agents in type 2 diabetes. These observed benefits in GV and hypoglycemia may contribute to the cardiovascular outcome reduction seen with GLP-1 RA therapy and should be investigated further.
Novel Fc-Engineered Antibodies to CD37 with Pro-Apoptotic and Enhanced ADCC Activity
Authors: Karl-Heinz Heider, Elinborg Ostermann, Herbert Lamche, Zaruhi Kuepcue, Alexander Jacobi, Renate Konopitzky, Ulrich Hirt, Volker Reichardt, Eric Borges
Journal: Blood (2010)
Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
Authors: Vikram Mathews, Biju George, Farah Jijina, Cecil Ross, Reena Nair, Shashikant Apte, Geetha Narayanan, Atul Sharma, Kavitha M Lakshmi, Auro Viswabandya, Ezhilarasi Chendamarai, Poonkuzhali Balasubramanian, Vivi Srivastava, Mammen Chandy, Alok Srivastava
Journal: Blood (2011)
Assessment of Cardiac Iron Overload in Chonically Transfused Patients with Thalassemia, Sickle Cell Anemia, and Myelodysplastic Syndromes
Authors: Mariane De Montalembert, Jean-Antoine Ribeil, Valentine Brousse, Agnes Guerci-Bresler, Aspasia Stamatoullas, Jean Pierre Vannier, Agnes Lahary, Mohamed Touati, Krimo Bouabdallah, Marina Cavazzana, Emmanuelle Chauzit, Amandine Baptiste, Thibaud Lefebvre, Herve Puy, Caroline Elie, Zoubida Karim, Olivier Ernst, Christian Rose
Journal: Blood (2015)
Efficacy, Safety and Economic Evaluation of Recombinant Activated Factor VII (rFVIIa) in the Management of Mild and Moderate Bleedings in Haemophilia Patients with Inhibitors in Brazil.
Authors: Margareth C. Ozelo, Paula R. Villaça, Telma Bueno, Jussara Almeida, Paulo A. Miranda, Warren M. Hart
Journal: Blood (2006)
SP1 and NF-Y-Dependent Gene Transactivation Defines a Gain-of-Function for the PML-RARα Oncoprotein.
Authors: Sake van Wageningen, Marleen C. Breems-de Ridder, Gorica Nikoloski, Claudia A.J. Erpelinck-Verschueren, Jeannet Nigten, Bob Löwenberg, Theo de Witte, Bert A. van der Reijden, Joop H. Jansen
Journal: Blood (2005)
Time To Complete Remission Is Not a Significant Prognostic Factor in AML: A Report on 1,959 Consecutive Patients Registered to 6 Studies of the Eastern Cooperative Oncology Group (ECOG).
Authors: Jacob M. Rowe, Haesook T. Kim, Peter A. Cassileth, Mark R. Litzow, Peter H. Wiernik, Martin S. Tallman
Journal: Blood (2004)
UK clinics may be able to offer mitochrondrial donation next spring
Authors: Nigel Hawkes
Journal: BMJ (2016)

A scientific panel has given the go ahead for use of mitochondrial donation in carefully selected women to improve their chances of having children free of inherited mitochondrial diseases.1

The technique involves substituting healthy mitochondrial DNA from a donor egg for the abnormal version carried by the mother’s eggs, before or after the egg has been fertilised. The resulting embryo, with nuclear DNA from the mother and the father and mitochondrial DNA from the donor, is then implanted in the mother’s womb.

The Human Fertilisation and Embryology Authority set up the panel after parliament last year approved the use of two techniques for mitochondrial donation.2 3 4 5 The panel’s remit was to advise whether the procedures were ready for clinical application. It has determined that they are, subject to some caveats.

The report will now go to the authority for consideration at a meeting on 15 December. If it agrees, in vitro fertilisation (IVF) clinics will be able to apply for a licence to perform the procedure. Those granted a licence will then have to submit case by case justifications …
FLC Assay and Multiparameter Flowcytometry Based Clonal Plasma Cell Measurement Are Independent but Complementary in Assessing the Treatment Response in Multiple Myeloma.
Authors: Hiroki Sugihara, Kenji Tsuda, Tomotaka Ugai, Yuki Nishida, Masayuki Yamakura, Masami Takeuchi, Kosei Matsue
Journal: Blood (2012)
Identification of Three Tyrosine Phosphorylation Sites in the p53 Binding Domain of Apoptosis-Stimulating p53 Protein 2 (ASPP2) That Are Differentially Phosphorylated in Response to Chemotherapy in Patient Derived AML Blasts
Authors: Kerstin M Kampa-Schittenhelm, Charles D Lopez, Marcus M Schittenhelm
Journal: Blood (2011)
Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity
Authors: G. Cortellini, A. Romano, A. Santucci, A. Barbaud, S. Bavbek, D. Bignardi, M. Blanca, P. Bonadonna, M. T. Costantino, J. J. Laguna, C. Lombardo, L.M. Losappio, J. Makowska, A. Nakonechna, O. Quercia, E. A. Pastorello, V. Patella, I. Terreehorst, S. Testi, J. R. Cernadas, J. Dionicio Elera, D. Lippolis, S. Voltolini, D. Grosseto
Journal: Allergy (2016)

Background Hypersensitivity to acetylsalicylic acid (ASA) constitutes a serious problem for subjects with coronary artery disease. In such subjects, physicians have to choose the more appropriate procedure between challenge and desensitization. As the literature on this issue is sparse, this study aimed to establish in these subjects clinical criteria for eligibility for an ASA challenge and/or desensitization. Methods Collection and analysis of data on ASA challenges and desensitizations from 10 allergy centers, as well as consensus among the related physicians and an expert panel. Results Altogether, 310 subjects were assessed; 217 had histories of urticaria/angioedema, 50 of anaphylaxis, 26 of nonimmediate cutaneous eruptions, and 17 of bronchospasm related to ASA/nonsteroidal anti-inflammatory drugs (NSAID) intake. Specifically, 119 subjects had index reactions to ASA doses lower than 300 mg. Of the 310 subjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent desensitizations, whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent challenges. Overall, 163 subjects underwent challenges and 147 subjects underwent desensitizations; 86 of the latter had index reactions to ASA doses of 300 mg or less. Ten subjects reacted to challenges, seven at doses up to 500 mg, three at a cumulative dose of 110 mg. The desensitization failure rate was 1.4%. Conclusions In patients with stable CIHD and histories of nonsevere hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable. Patients with an ACS and histories of hypersensitivity reactions to ASA, especially following doses lower than 100 mg, should directly undergo desensitization.
Gemtuzumab Ozogamicin as Induction Therapy Followed by Post-Remission Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia
Authors: Heeje Kim, Ki-Seong Eom, Byung-Sik Cho, Jong-Wook Lee, Woo-Sung Min, Chun-Choo Kim
Journal: Blood (2008)
Exposure to Corticoid-Sparing Treatments in Adult Primary Immune Thrombocytopenia before the Chronic Phase in the Era of Thrombopoietin Receptor Agonists in France. a Nationwide Population-Based Study
Authors: Guillaume Moulis, Maryse Lapeyre-Mestre, Jean-Louis Montastruc, Bertrand Godeau, Laurent Sailler
Journal: Blood (2014)